Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 0.4%

Pasithea Therapeutics Corp. (NASDAQ:KTTAGet Free Report)’s share price fell 0.4% on Thursday . The company traded as low as $7.12 and last traded at $7.12. 702 shares traded hands during trading, a decline of 93% from the average session volume of 9,970 shares. The stock had previously closed at $7.15.

Pasithea Therapeutics Trading Down 0.4 %

The stock has a 50-day moving average price of $7.32 and a two-hundred day moving average price of $7.30.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pasithea Therapeutics stock. Vanguard Group Inc. boosted its position in Pasithea Therapeutics Corp. (NASDAQ:KTTAFree Report) by 104.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 159,844 shares of the company’s stock after purchasing an additional 81,705 shares during the period. Vanguard Group Inc. owned approximately 0.60% of Pasithea Therapeutics worth $201,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 23.92% of the company’s stock.

About Pasithea Therapeutics

(Get Free Report)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers.

Featured Articles

Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with's FREE daily email newsletter.